AC Immune SA (ACIU)
AC Immune SA Statistics
Share Statistics
AC Immune SA has 98.94M shares outstanding. The number of shares has increased by -0.26% in one year.
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | -0.26% |
| Shares Change (QoQ) | -0.74% |
| Owned by Institutions (%) | 24.87% |
| Shares Floating | 61.45M |
| Failed to Deliver (FTD) Shares | 6 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 1.01M, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 7.04 |
Valuation Ratios
The PE ratio is -5.3 and the forward PE ratio is -34.29. AC Immune SA's PEG ratio is 0.19.
| PE Ratio | -5.3 |
| Forward PE | -34.29 |
| PS Ratio | 9.88 |
| Forward PS | 0.6 |
| PB Ratio | 2.4 |
| P/FCF Ratio | 4.13 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for AC Immune SA.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.71 |
| Quick Ratio | 1.71 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | 0.08 |
| Interest Coverage | -393.82 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $205.33K |
| Profits Per Employee | $-382.83K |
| Employee Count | 133 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -35.27% in the last 52 weeks. The beta is 1.22, so AC Immune SA's price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | -35.27% |
| 50-Day Moving Average | 2.42 |
| 200-Day Moving Average | 3.08 |
| Relative Strength Index (RSI) | 25.21 |
| Average Volume (20 Days) | 202.92K |
Income Statement
In the last 12 months, AC Immune SA had revenue of 27.31M and earned -50.92M in profits. Earnings per share was -0.46.
| Revenue | 27.31M |
| Gross Profit | 27.31M |
| Operating Income | -52.38M |
| Net Income | -50.92M |
| EBITDA | -48.62M |
| EBIT | -50.78M |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
The company has 36.27M in cash and 5.43M in debt, giving a net cash position of 30.85M.
| Cash & Cash Equivalents | 36.27M |
| Total Debt | 5.43M |
| Net Cash | 30.85M |
| Retained Earnings | -368.24M |
| Total Assets | 230.91M |
| Working Capital | 71.16M |
Cash Flow
In the last 12 months, operating cash flow was 65.84M and capital expenditures -576K, giving a free cash flow of 65.27M.
| Operating Cash Flow | 65.84M |
| Capital Expenditures | -576K |
| Free Cash Flow | 65.27M |
| FCF Per Share | 0.59 |
Margins
Gross margin is 100%, with operating and profit margins of -191.8% and -186.44%.
| Gross Margin | 100% |
| Operating Margin | -191.8% |
| Pretax Margin | -186.43% |
| Profit Margin | -186.44% |
| EBITDA Margin | -178.03% |
| EBIT Margin | -191.8% |
| FCF Margin | 238.99% |
Dividends & Yields
ACIU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ACIU is $12, which is 574.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 574.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.6 |
| Piotroski F-Score | 4 |